NO20053430L - Sammensetninger og fremgangsmater for foroket mukosal levering av Y2 reseptor-bindende peptider og fremgangsmater for behandling og forebygging av fedme. - Google Patents

Sammensetninger og fremgangsmater for foroket mukosal levering av Y2 reseptor-bindende peptider og fremgangsmater for behandling og forebygging av fedme.

Info

Publication number
NO20053430L
NO20053430L NO20053430A NO20053430A NO20053430L NO 20053430 L NO20053430 L NO 20053430L NO 20053430 A NO20053430 A NO 20053430A NO 20053430 A NO20053430 A NO 20053430A NO 20053430 L NO20053430 L NO 20053430L
Authority
NO
Norway
Prior art keywords
methods
peptide
subject
fluid
compositions
Prior art date
Application number
NO20053430A
Other languages
English (en)
Other versions
NO20053430D0 (no
Inventor
Steven C Quay
Gordon Brandt
Mary S Kleppe
Conor J Macevilly
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/322,266 external-priority patent/US7166575B2/en
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of NO20053430D0 publication Critical patent/NO20053430D0/no
Publication of NO20053430L publication Critical patent/NO20053430L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det er beskrevet farmasøytiske sammensetninger og fremgangsmåter som omfatter minst én peptid YY-forbindelse og ett eller flere intranasale leveringsfremmende agenser for forøket nasal mukosal levering av peptidet YY, for behandling av mange forskjellige sykdommer og tilstander hos mammalske subjekter, inkludert fedme. I ett aspekt tilveiebringer de intranasale leveringsformuleringene og fremgangsmåtene forøket levering av peptid YY til blodplasma eller sentralnervesystem (CNS)-vev eller væske, for eksempel ved å gi en toppkonsentrasjon (Cmax) av peptidet YY i blodplasma eller CNS-vev eller væske hos subjektet som er 20% eller høyere sammenlignet med en topp-konsentrasjon av peptidet YY i blodplasma eller CNS-vev eller væske hos subjektet etter administrering til subjektet av en samme konsentrasjon eller dose av peptidet YY til subjektet ved subkutan injeksjon.
NO20053430A 2002-12-17 2005-07-14 Sammensetninger og fremgangsmater for foroket mukosal levering av Y2 reseptor-bindende peptider og fremgangsmater for behandling og forebygging av fedme. NO20053430L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/322,266 US7166575B2 (en) 2002-12-17 2002-12-17 Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US49322603P 2003-08-07 2003-08-07
US50117003P 2003-09-08 2003-09-08
US51078503P 2003-10-10 2003-10-10
US51729003P 2003-11-04 2003-11-04
US51881203P 2003-11-10 2003-11-10
PCT/US2003/040538 WO2004056314A2 (en) 2002-12-17 2003-12-17 Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity

Publications (2)

Publication Number Publication Date
NO20053430D0 NO20053430D0 (no) 2005-07-14
NO20053430L true NO20053430L (no) 2005-09-15

Family

ID=32686401

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053430A NO20053430L (no) 2002-12-17 2005-07-14 Sammensetninger og fremgangsmater for foroket mukosal levering av Y2 reseptor-bindende peptider og fremgangsmater for behandling og forebygging av fedme.

Country Status (13)

Country Link
US (4) US7186691B2 (no)
EP (1) EP1581245A2 (no)
JP (1) JP2006516262A (no)
AU (1) AU2003299722A1 (no)
BR (1) BR0316685A (no)
CA (1) CA2510199A1 (no)
CO (1) CO5700705A2 (no)
EA (1) EA008829B1 (no)
EC (1) ECSP055839A (no)
MA (1) MA27535A1 (no)
MX (1) MXPA05006572A (no)
NO (1) NO20053430L (no)
WO (1) WO2004056314A2 (no)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2569916T3 (es) 1999-06-29 2016-05-13 Mannkind Corporation Formulaciones farmacéuticas que comprenden insulina complejada con una dicetopiperazina
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
WO2004066966A2 (en) * 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide yy analogs
EP1713514B1 (en) * 2004-01-28 2021-11-24 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
WO2005078454A2 (en) * 2004-02-09 2005-08-25 Nastech Pharmaceutical Company Inc. Methods for determining the amount of peptide yy in blood
DE602005014962D1 (de) 2004-03-12 2009-07-30 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
CA2560174A1 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
US9399054B2 (en) * 2004-07-12 2016-07-26 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
JP2008507280A (ja) * 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
PA8660701A1 (es) * 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
MX2007009544A (es) * 2005-02-08 2008-03-19 Woodford Associates Ltd Bebida sin alcohol enriquecida con 1h2 16o.
DE602005027492D1 (de) * 2005-02-08 2011-05-26 Sergey Pavlovich Soloviev Mit 1h2160 angereichertes alkoholisches getränk
BRPI0520147A2 (pt) * 2005-03-05 2009-04-22 Sergey Pavlovich Soloviev composiÇÕes cosmÉticas enriquecidas com 1h2 16o
EP1883296A1 (en) * 2005-03-11 2008-02-06 VADA Consulting Limited Compositions for disinfecing inanimate surfaces
US20080160100A1 (en) * 2005-03-11 2008-07-03 Igor Anatolievich Pomytkin Method For Stimulating Hair Growth And Regeneration
US20080103092A1 (en) * 2005-03-11 2008-05-01 Pomytkin Igor A Methods for Intradermal, Transdermal or Transmucosal Delivery of Biologically Active Substances
WO2006098650A1 (en) * 2005-03-11 2006-09-21 Vada Consulting Limited Light pharmaceutical water and therapeutic compositions and methods thereof
RU2275920C1 (ru) * 2005-04-01 2006-05-10 Игорь Анатольевич Помыткин Способ лечения новообразований
JP2009500453A (ja) * 2005-07-11 2009-01-08 ナステック ファーマスーティカル カンパニー インク． 向上されたｐｙｙの粘膜送達用製剤
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
WO2007069934A1 (en) * 2005-12-12 2007-06-21 Vada Consulting Limited Method of treating metabolic syndrome
EA014535B1 (ru) * 2005-12-12 2010-12-30 Тимантти Аб Способ подавления аппетита и снижения объема поглощения пищи
WO2007070564A2 (en) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Methods of treating obesity using enterostatin
WO2007070563A2 (en) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Stable solid forms of enterostatin
WO2007070562A2 (en) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Non-hygroscopic compositions of enterostatin
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
EP2029157A4 (en) 2006-05-19 2009-11-18 Georgia Tech Res Inst ABC TRANSPORTERLIGAND
RU2301067C1 (ru) * 2006-06-19 2007-06-20 Сергей Павлович Соловьев Средство и способ для повышения половой активности человека
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
EP2051725A4 (en) * 2006-07-11 2011-06-15 Harkness Pharmaceuticals Inc METHOD FOR THE TREATMENT OF GRAIN WITH SATURATION FACTORS
US8324158B2 (en) 2006-07-14 2012-12-04 Georgia Tech Research Corporation Methods for inhibiting CLC-2 channel with GATX2
WO2008012629A2 (en) 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Exendin fusion proteins
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
GB0708226D0 (en) * 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US8889622B2 (en) * 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
US20100204113A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of stresscopin-related peptide as a therapeutic agent
NZ586947A (en) * 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
CA2758415C (en) 2008-04-14 2019-06-04 The General Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
WO2010068414A2 (en) * 2008-11-25 2010-06-17 Bowen Richard L Methods for treating obesity related disease
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
US20110110911A1 (en) * 2009-08-14 2011-05-12 Allergan, Inc Methods of Treating Cancer Using Tachykinin Retargeted Endopepidases
US8207651B2 (en) 2009-09-16 2012-06-26 Tyco Healthcare Group Lp Low energy or minimum disturbance method for measuring frequency response functions of ultrasonic surgical devices in determining optimum operating point
KR101026864B1 (ko) 2009-10-08 2011-04-12 (주)송호바이오메드 고 수용성 ２―하이드록시프로필―베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
AU2011265294B2 (en) 2010-06-10 2015-01-22 Aquestive Therapeutics, Inc. Nanoparticle film delivery systems
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
RU2476227C2 (ru) * 2011-04-14 2013-02-27 Ольга Георгиевна Мельникова Способ снижения избыточного веса
DE102011103347B4 (de) * 2011-05-27 2014-10-30 Meda Pharma Gmbh & Co. Kg Nasale pharmazeutische Formulierung
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
AU2012352528B9 (en) * 2011-12-11 2017-11-02 Baudax Bio, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256064B2 (en) 2012-05-03 2018-01-04 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102310775B1 (ko) 2012-05-03 2021-10-07 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
ES2729970T3 (es) * 2013-04-10 2019-11-07 Univ Copenhagen Péptidos derivados de neuropéptidos y
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN107635545A (zh) 2015-01-27 2018-01-26 约翰霍普金斯大学 用于增强粘膜表面处活性剂的输送的低渗水凝胶制剂
US20170081366A1 (en) * 2015-09-22 2017-03-23 Kyungpook National University Industry - Academic Cooperation Foundation Novel Peptides for Preventing or Treating Bone Diseases and Use Thereof
CN108367079B (zh) 2015-11-12 2022-11-22 灰色视觉公司 用于治疗的聚集性微粒
US11160870B2 (en) 2017-05-10 2021-11-02 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
US12240890B2 (en) * 2017-05-16 2025-03-04 The University Of Chicago Compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism
JP2021512051A (ja) 2018-01-23 2021-05-13 ギラ セラピューティクス インコーポレイテッドＧｉｌａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドｙｙ薬学的調剤物、組成物、および方法
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
EP4404912A1 (en) * 2021-09-22 2024-07-31 Ferring B.V. Adrenocorticotropic hormone peptide compositions and methods of use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657779A5 (de) * 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5725804A (en) * 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US6391343B1 (en) * 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
EP0495187B1 (en) * 1991-01-15 1997-01-22 Hemosphere, Inc. Protein nanomatrixes and method of production
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
CA2139764C (en) * 1992-07-07 1999-02-23 Wayne N. Collette Method of forming multi-layer preform and container with low-crystallizing interior layer
NZ261250A (en) 1993-01-06 1997-08-22 Kinerton Ltd Ionic conjugates of polypeptides
SK121895A3 (en) * 1993-03-29 1996-10-02 Univ Cincinnati Analogues of peptide yy and uses thereof
EP0788509B1 (en) 1993-08-09 2003-05-28 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Therapeutic peptide derivatives
US5696093A (en) * 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) * 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5912227A (en) * 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
JPH11505258A (ja) * 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US6017897A (en) * 1995-06-07 2000-01-25 Pasteur Merieux Connaught Canada Nucleic acid respiratory syncytial virus vaccines
US5716643A (en) * 1995-06-07 1998-02-10 Hemosphere Inc. Large scale production of medicine coated crosslinked protein microspheres
FR2736265B1 (fr) * 1995-07-07 1997-09-26 Forgeot Marcel Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
CA2271788A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
WO1998055105A1 (en) * 1997-06-05 1998-12-10 Hemosphere, Inc. Fibrinogen-coated microspheres
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
IT1293088B1 (it) 1997-07-10 1999-02-11 Isi Ist Sierovaccinogeno Ital Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
AU9185598A (en) 1997-09-25 1999-04-12 Banyu Pharmaceutical Co., Ltd. Novel neuropeptide y receptor antagonists
AR014069A1 (es) 1998-01-29 2001-01-31 Kinerton Ltd Procedimiento para preparar microparticula o microparticulas unidas encapsuladas
US6046167A (en) * 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
US6017879A (en) * 1998-04-03 2000-01-25 B.M.R.A. Corporation B.V. Template associated NPY Y2-receptor agonists
US7745216B2 (en) * 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
DE60045030D1 (de) 1999-02-10 2010-11-11 Curis Inc Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
US8273713B2 (en) 2000-12-14 2012-09-25 Amylin Pharmaceuticals, Llc Methods of treating obesity using PYY[3-36]
KR100989647B1 (ko) * 2001-09-24 2010-10-26 오레곤 헬스 앤드 사이언스 유니버시티 식습관의 변화
IL161446A0 (en) 2001-11-26 2004-09-27 Daiichi Suntory Pharma Co Ltd Medicinal compositions for nasal absorption
EP1474163A2 (en) 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
ATE494002T1 (de) 2002-06-14 2011-01-15 Amylin Pharmaceuticals Inc Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü

Also Published As

Publication number Publication date
JP2006516262A (ja) 2006-06-29
MXPA05006572A (es) 2005-12-14
US7186691B2 (en) 2007-03-06
EA200501007A1 (ru) 2006-02-24
US20040209807A1 (en) 2004-10-21
EA008829B1 (ru) 2007-08-31
MA27535A1 (fr) 2005-09-01
CO5700705A2 (es) 2006-11-30
AU2003299722A1 (en) 2004-07-14
ECSP055839A (es) 2006-03-01
CA2510199A1 (en) 2004-07-08
US20040157777A1 (en) 2004-08-12
US7157426B2 (en) 2007-01-02
WO2004056314A3 (en) 2005-03-31
WO2004056314B1 (en) 2005-09-29
US20070197437A1 (en) 2007-08-23
EP1581245A2 (en) 2005-10-05
WO2004056314A2 (en) 2004-07-08
NO20053430D0 (no) 2005-07-14
BR0316685A (pt) 2005-11-01
US20070129299A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
NO20053430L (no) Sammensetninger og fremgangsmater for foroket mukosal levering av Y2 reseptor-bindende peptider og fremgangsmater for behandling og forebygging av fedme.
MXPA05013340A (es) Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
WO2021047648A1 (en) New peptides
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
DE69431290D1 (de) PULMONÄRE VERABREICHUNG DES LÖSLICHEN KOMPLEMENT-RECEPTORS TYP 1 sCR1
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
US12337065B2 (en) Compositions for treating viral infections and methods for same
WO2002043746A3 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
EA200501710A1 (ru) Замещённые карбоновые кислоты
NO20015931L (no) Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin
NO330954B1 (no) Anvendelse av en forbindelse for fremstilling av et legemiddel for behandling av en pasient som lider av sarkoidose.
KR20250143851A (ko) 신규한 다기능성 올리고펩타이드
DE59308848D1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US20240218016A1 (en) Peptides and their use in the treatment of inflammation
ES2842523T3 (es) Métodos y composiciones para el tratamiento de la artritis
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
Morrison et al. Juvenile respiratory papillomatosis: acyclovir reassessed
TNSN05162A1 (en) Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
BR0316123A (pt) Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico
NO20016301L (no) Terapeutiske midler
US12612430B2 (en) Peptides
TW200509960A (en) Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application